NASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis $77.11 +2.08 (+2.77%) Closing price 08/17/2026 04:00 PM EasternExtended Trading$76.68 -0.42 (-0.55%) As of 07:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CG Oncology Stock (NASDAQ:CGON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CG Oncology alerts:Sign Up Key Stats Today's Range$73.87▼$77.4250-Day Range$54.92▼$77.1152-Week Range$24.85▼$79.39Volume958,312 shsAverage Volume805,454 shsMarket Capitalization$6.84 billionP/E RatioN/ADividend YieldN/APrice Target$83.18Consensus RatingModerate Buy Company Overview CG Oncology, Inc. (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity. Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates. The company’s discovery engine integrates high-throughput screening, structure-based design and biomarker development, enabling rapid iteration and selection of molecules with favorable pharmacological profiles. Since its founding, CG Oncology has built a management team with extensive experience in oncology drug development, regulatory strategy and commercial planning. The organization continues to expand its pipeline by pursuing additional immuno-oncology targets and exploring strategic collaborations to accelerate the translation of its antibody assets from preclinical research into the clinic. Through these efforts, CG Oncology aims to create differentiated therapies that address unmet needs in the treatment of solid tumor malignancies. AI Generated. May Contain Errors. Read More CG Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreCGON MarketRank™: CG Oncology scored higher than 43% of companies evaluated by MarketBeat, and ranked 583rd out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingModerate Buy Consensus RatingCG Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for CG Oncology is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageCG Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CG Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CG Oncology are expected to grow in the coming year, from ($3.25) to ($3.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CG Oncology is -28.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CG Oncology is -28.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCG Oncology has a P/B Ratio of 8.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.04% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 13.53, which indicates bearish sentiment.Change versus previous monthShort interest in CG Oncology has recently decreased by 2.16%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.35 News SentimentCG Oncology has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CG Oncology this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for CGON on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows8 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $22,150,637.00 in company stock, which represents 0.3241% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have bought 831.54% more of their company's stock than they have sold. Specifically, they have bought $24,814,454.00 in company stock and sold $2,663,817.00 in company stock.Percentage Held by Insiders4.80% of the stock of CG Oncology is held by insiders.Percentage Held by Institutions26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGON Stock News HeadlinesCG Oncology: Circling Back After Huge RallyAugust 13, 2026 | seekingalpha.comRoyal Bank Of Canada Cuts CG Oncology (NASDAQ:CGON) Price Target to $79.00August 10, 2026 | americanbankingnews.comThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the project. Unocal and Texaco did the same. All three buried the results because it threatened their core business. Now one company has spent sixty years developing what Big Oil refused to touch. Google locked in a 15-year contract, Bill Gates wrote a $100 million check, and on August 18th the government hands it a competitive edge no other energy source receives.August 18 at 1:00 AM | Behind the Markets (Ad)CG Oncology (NASDAQ:CGON) Price Target Raised to $85.00August 10, 2026 | americanbankingnews.comQ3 EPS Estimates for CG Oncology Lowered by HC WainwrightAugust 10, 2026 | americanbankingnews.comFY2029 EPS Estimates for CG Oncology Decreased by AnalystAugust 9, 2026 | americanbankingnews.comCG Oncology Highlights Q2 Results and Pipeline ProgressAugust 6, 2026 | tipranks.comCG Oncology Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 6, 2026 | globenewswire.comSee More Headlines CGON Stock Analysis - Frequently Asked Questions How have CGON shares performed this year? CG Oncology's stock was trading at $41.52 on January 1st, 2026. Since then, CGON stock has increased by 85.7% and is now trading at $77.11. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by $0.24. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.36 million. CG Oncology had a negative trailing twelve-month return on equity of 25.20% and a negative net margin of 3,602.68%. When did CG Oncology IPO? CG Oncology (CGON) raised $340 million in an initial public offering (IPO) on Thursday, January 25th 2024. The company issued 20,000,000 shares at a price of $16.00-$18.00 per share. Who are CG Oncology's major shareholders? Top institutional shareholders of CG Oncology include BlackRock Inc. (7.09%), Seven Fleet Capital Management LP (2.13%), Bank of America Corp DE (1.11%) and Jefferies Financial Group Inc. (0.87%). Insiders that own company stock include Hong Fang Song, Brian Guan-Chyun Liu, Decheng Capital Global Life Sc, James Mulay, Corleen M Roche and Vijay Kasturi. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CG Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings8/06/2026Today8/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CGON's financial health is in the Green zone, according to TradeSmith. CGON has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CIK1991792 Webcgoncology.com Phone949-419-6203FaxN/AEmployees61Year Founded2010Price Target and Rating Average Price Target for CG Oncology$83.18 High Price Target$100.00 Low Price Target$50.00 Potential Upside/Downside+7.9%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$160.99 million Net Margins-3,602.68% Pretax Margin-3,602.68% Return on Equity-25.20% Return on Assets-23.98% Debt Debt-to-Equity RatioN/A Current Ratio22.22 Quick Ratio22.20 Sales & Book Value Annual Sales$4.04 million Price / Sales1,691.84 Cash FlowN/A Price / Cash FlowN/A Book Value$9.33 per share Price / Book8.26Miscellaneous Outstanding Shares88,640,000Free Float84,385,000Market Cap$6.84 billion OptionableOptionable Beta0.23 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CGON) was last updated on 8/18/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War: What Happened at 1:11 P.M. Outside D.C.?A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...Banyan Hill Publishing | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA Wall Street veteran shares two simple trading rulesA self-described Market Wizard says two simple rules, refined over decades on Wall Street, form the basis of h...Brownstone Research | Sponsored19 Factories. One AI Brain. One Hidden Stock.A little-known aerospace manufacturer has linked 19 factories worldwide into a single AI-ready data system, dr...The Oxford Club | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredA Dark Day Is Coming to AmericaKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
